Recently, a randomized, double-blind and placebo-controlled study reported that one glucokinase activator, TTP399, can lower HbA1C and reduce hypoglycemia without increasing the risk of ketosis in patients with T1D44. This evidence concerns the gene GCK and Hypoglycemia.